Literature DB >> 16286444

Development of a short form of the Severe Impairment Battery.

Judith Saxton1, Kari B Kastango, Laurence Hugonot-Diener, Francois Boller, Marc Verny, C Elizabeth Sarles, Ragy R Girgis, Emmanuel Devouche, Patrizia Mecocci, Bruce G Pollock, Steven T DeKosky.   

Abstract

OBJECTIVE: The authors sought to develop a short form of the Severe Impairment Battery (SIB).
METHODS: Authors describe the development of an empirically-derived short form of the SIB (SIB-S) by use of data from 191 subjects with severe dementia in the United States and France.
RESULTS: Mean (standard deviation) Mini-Mental State Exam scores for the American and French samples were 7.7 (4.8) and 5.7 (3.4), respectively, and original SIB scores were 71.87 (18.34) and 58.38 (26.86), respectively. Exploratory factor analyses were conducted separately and in combination for the two samples, to determine the number of clinically meaningful factors. An eight-factor model, explaining 60.2% of the common variance, was selected. The eight constructs were described as: expressive language, memory (verbal and nonverbal), social interaction, color-naming, praxis, reading and writing, fluency, and attention. Derived SIB-S scores were 38.41 (9.12) and 29.79 (13.17) for the American and French samples, respectively.
CONCLUSIONS: The original SIB is a valid and reliable research tool developed to enable reliable assessment of patients with severe dementia; it takes approximately 30 minutes to administer. The SIB-S takes only 10-15 minutes to administer, making it more appropriate for use in patients with very severe dementia, while it maintains the attributes of the original SIB.

Entities:  

Mesh:

Year:  2005        PMID: 16286444     DOI: 10.1176/appi.ajgp.13.11.999

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  21 in total

1.  Cognitive decline and brain amyloid-β accumulation across 3 years in adults with Down syndrome.

Authors:  Sigan L Hartley; Benjamin L Handen; Darlynne Devenny; Iulia Mihaila; Regina Hardison; Patrick J Lao; William E Klunk; Peter Bulova; Sterling C Johnson; Bradley T Christian
Journal:  Neurobiol Aging       Date:  2017-06-02       Impact factor: 4.673

2.  Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?

Authors:  Philippe Robert; Steven Ferris; Serge Gauthier; Ralf Ihl; Bengt Winblad; Frank Tennigkeit
Journal:  Alzheimers Res Ther       Date:  2010-08-26       Impact factor: 6.982

3.  Prevalence of behavioral symptoms: comparison of the minimum data set assessments with research instruments.

Authors:  Ashok J Bharucha; Mihnea Vasilescu; Mary Amanda Dew; Amy Begley; Scott Stevens; Howard Degenholtz; Howard Wactlar
Journal:  J Am Med Dir Assoc       Date:  2008-04-08       Impact factor: 4.669

4.  Effects of Physical Activity in Nursing Home Residents with Dementia: A Randomized Controlled Trial.

Authors:  Marinda Henskens; Ilse M Nauta; Marieke C A van Eekeren; Erik J A Scherder
Journal:  Dement Geriatr Cogn Disord       Date:  2018-08-24       Impact factor: 2.959

5.  Research protocol of the NeedYD-study (Needs in Young onset Dementia): a prospective cohort study on the needs and course of early onset dementia.

Authors:  Deliane van Vliet; Christian Bakker; Raymond T C M Koopmans; Myrra J F J Vernooij-Dassen; Frans R J Verhey; Marjolein E de Vugt
Journal:  BMC Geriatr       Date:  2010-03-12       Impact factor: 3.921

6.  Consequences from use of reminiscence--a randomised intervention study in ten Danish nursing homes.

Authors:  Claire Gudex; Charlotte Horsted; Anders Møller Jensen; Marianne Kjer; Jan Sørensen
Journal:  BMC Geriatr       Date:  2010-06-06       Impact factor: 3.921

7.  Cognitive functioning in relation to brain amyloid-β in healthy adults with Down syndrome.

Authors:  Sigan L Hartley; Benjamin L Handen; Darlynne A Devenny; Regina Hardison; Iulia Mihaila; Julie C Price; Annie D Cohen; William E Klunk; Marsha R Mailick; Sterling C Johnson; Bradley T Christian
Journal:  Brain       Date:  2014-07-02       Impact factor: 13.501

8.  Evaluating Residual Cognition in Advanced Cognitive Impairment: The Residual Cognition Assessment.

Authors:  Alex Soli; Giacomina Savoldelli; Angelica Rota; Sara Zonca; Gloria Belotti; Fabrizio Lazzarini
Journal:  Dement Geriatr Cogn Disord       Date:  2021-12-08       Impact factor: 2.959

9.  Analyzing the impact of 23 mg/day donepezil on language dysfunction in moderate to severe Alzheimer's disease.

Authors:  Steven H Ferris; Frederick A Schmitt; Judith Saxton; Sharon Richardson; Joan Mackell; Yijun Sun; Yikang Xu
Journal:  Alzheimers Res Ther       Date:  2011-06-20       Impact factor: 6.982

10.  Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity.

Authors:  Steven Ferris; Jeffrey Cummings; Daniel Christensen; Rachelle Doody; Martin Farlow; Marwan Sabbagh; Liang Liu; Joan Mackell; Randi Fain
Journal:  Alzheimers Res Ther       Date:  2013-02-21       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.